APA (7th ed.) Citation

Tessoulin, B., Beyne-RAuzy, O., Guerci, A., Gyan, E., Hunault, M., Ianotto, J., . . . Delaunay, J. (2013). P-309 Low/intermerdiate-1 risk MDS treated with high-dose rHu-EPO: Hematological responses and impact on quality of life, a prospective GFM study. Leukemia Research, 37, S161. https://doi.org/10.1016/S0145-2126(13)70356-4

Chicago Style (17th ed.) Citation

Tessoulin, B., et al. "P-309 Low/intermerdiate-1 Risk MDS Treated with High-dose RHu-EPO: Hematological Responses and Impact on Quality of Life, a Prospective GFM Study." Leukemia Research 37 (2013): S161. https://doi.org/10.1016/S0145-2126(13)70356-4.

MLA (9th ed.) Citation

Tessoulin, B., et al. "P-309 Low/intermerdiate-1 Risk MDS Treated with High-dose RHu-EPO: Hematological Responses and Impact on Quality of Life, a Prospective GFM Study." Leukemia Research, vol. 37, 2013, p. S161, https://doi.org/10.1016/S0145-2126(13)70356-4.